(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
2.06% ¥ 347.00
Live Chart Being Loaded With Signals
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, such as Trumpet Intestinal Regulator BF...
Stats | |
---|---|
Volumen de hoy | 99 000.00 |
Volumen promedio | 488 822 |
Capitalización de mercado | 17.40B |
EPS | ¥0 ( 2024-02-08 ) |
Próxima fecha de ganancias | ( ¥0 ) 2024-05-09 |
Last Dividend | ¥13.00 ( 2021-12-29 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -4.55 |
ATR14 | ¥0.925 (0.27%) |
Volumen Correlación
Taiko Pharmaceutical Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Taiko Pharmaceutical Correlación - Moneda/Commodity
Taiko Pharmaceutical Finanzas
Annual | 2022 |
Ingresos: | ¥5.04B |
Beneficio Bruto: | ¥1.08B (21.41 %) |
EPS: | ¥-112.24 |
FY | 2022 |
Ingresos: | ¥5.04B |
Beneficio Bruto: | ¥1.08B (21.41 %) |
EPS: | ¥-112.24 |
FY | 2021 |
Ingresos: | ¥10.72B |
Beneficio Bruto: | ¥2.75B (25.63 %) |
EPS: | ¥-91.46 |
FY | 2020 |
Ingresos: | ¥17.68B |
Beneficio Bruto: | ¥12.42B (70.24 %) |
EPS: | ¥89.18 |
Financial Reports:
No articles found.
Taiko Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
First Dividend | ¥0.556 | 2009-03-26 |
Last Dividend | ¥13.00 | 2021-12-29 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | ¥72.22 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.18 | -- |
Div. Sustainability Score | 0.484 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6866.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
6238.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
4963.T | Ex Dividend Junior | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
4118.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3349.T | Ex Dividend Knight | 2023-11-29 | Semi-Annually | 0 | 0.00% | |
2427.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
9364.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8056.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7309.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
6555.T | Ex Dividend Junior | 2024-02-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.375 | 1.500 | -7.50 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.144 | 1.200 | -4.80 | -5.76 | [0 - 0.3] |
returnOnEquityTTM | -0.261 | 1.500 | -4.01 | -6.02 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.19 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.54 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.719 | 1.500 | 1.560 | 2.34 | [0.2 - 2] |
debtRatioTTM | 0.188 | -1.500 | 6.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -85.89 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 30] |
freeCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 20] |
debtEquityRatioTTM | 0.305 | -1.500 | 8.78 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.394 | 1.000 | 6.76 | 6.76 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.127 | 1.000 | -4.55 | -4.55 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.384 | 0.800 | -0.775 | -0.620 | [0.5 - 2] |
Total Score | 0.484 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -6.82 | 1.000 | -0.790 | 0 | [1 - 100] |
returnOnEquityTTM | -0.261 | 2.50 | -2.58 | -6.02 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.124 | 1.500 | -4.16 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.598 |
Taiko Pharmaceutical
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, such as Trumpet Intestinal Regulator BF. It also manufactures and sells sanitation control products under the Cleverin brand name to wholesalers, as well as Cleverin generator, a machine that emits low concentrations of chlorine dioxide gas; and supplies products using the patented Cleverin technology through OEM agreements and products developed jointly with other companies. It exports its products to the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was incorporated in 1946 and is headquartered in Osaka, Japan.`
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico